05/14/2024 6:00 AM | ESSA Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/14/2024 6:01 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/06/2024 4:17 PM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/25/2024 9:35 AM | ESSA Pharma (Issuer) Glickman Richard M (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/05/2024 5:16 PM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/05/2024 2:02 PM | ESSA Pharma (Subject) Virsik Peter (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/28/2024 11:34 AM | ESSA Pharma (Issuer) Kantoff Philip W. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
03/28/2024 11:35 AM | ESSA Pharma (Issuer) Martin John Alexander (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:36 AM | ESSA Pharma (Issuer) Merendino Lauren (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:38 AM | ESSA Pharma (Issuer) Requadt Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:39 AM | ESSA Pharma (Issuer) Sollis Gary (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:40 AM | ESSA Pharma (Issuer) Thorell Marella (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:41 AM | ESSA Pharma (Issuer) ZWEIFACH SANFORD S (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:25 AM | Cesano Alessandra (Reporting) ESSA Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:27 AM | ESSA Pharma (Issuer) Parkinson David Ross (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:30 AM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:31 AM | ESSA Pharma (Issuer) Wood David S. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:32 AM | BERGER FRANKLIN M (Reporting) ESSA Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 11:33 AM | ESSA Pharma (Issuer) Glickman Richard M (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/07/2024 4:18 PM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/05/2024 5:50 PM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2024 6:05 AM | ESSA Pharma (Subject) RTW INVESTMENTS, LP (Filed by)
| Form SC 13G | |
02/13/2024 6:01 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/13/2024 6:01 AM | ESSA Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
02/13/2024 5:04 AM | BB BIOTECH AG (Filed by) ESSA Pharma (Subject)
| Form SC 13G/A | |
02/08/2024 10:29 AM | ESSA Pharma (Subject) MORGAN STANLEY (Filed by)
| Form SC 13G | |
02/07/2024 10:29 AM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/06/2024 7:27 AM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2024 8:15 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/23/2024 3:09 PM | ESSA Pharma (Subject) Soleus Capital, LLC (Filed by)
| Form SC 13G/A | |
01/17/2024 7:57 PM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/16/2024 12:41 PM | ESSA Pharma (Issuer) Requadt Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/12/2024 2:50 PM | ESSA Pharma (Subject) Gagnon Robert E. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2024 7:06 PM | ESSA Pharma (Issuer) Virsik Peter (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/18/2023 8:57 PM | ESSA Pharma (Issuer) Parkinson David Ross (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/12/2023 6:00 AM | ESSA Pharma (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
12/12/2023 6:01 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/24/2023 10:11 AM | ESSA Pharma (Issuer) Wood David S. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 5:22 PM | BERGER FRANKLIN M (Reporting) ESSA Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/16/2023 4:45 PM | BERGER FRANKLIN M (Reporting) ESSA Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/03/2023 8:44 PM | ESSA Pharma (Filer)
| Form 424B5 | |
It's time to ween off Chinese lithium! (Ad) As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution |
10/26/2023 7:07 PM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/23/2023 3:19 PM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/10/2023 11:15 PM | ESSA Pharma (Filer)
| Form EFFECT | |
10/03/2023 3:35 PM | ESSA Pharma (Filer)
| Form S-3/A | |
09/19/2023 3:43 PM | ESSA Pharma (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
09/18/2023 6:05 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/15/2023 6:56 PM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2023 6:15 AM | ESSA Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2023 6:01 AM | ESSA Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |